HealthCare Global Enterprises Ltd operates in oncology, providing comprehensive cancer diagnosis and treatment services including medical oncology, radiation therapy, and surgical oncology. It also offers fertility treatment services under the Milann brand, along with multi-specialty hospital care in key medical disciplines. The company’s operations span many metropolitan and non-metro cities across India and extend internationally with cancer care centers in Africa. HCG generates revenue through patient services in oncology, fertility treatments, diagnostics, and multi-specialty hospital care, leveraging technology and a networked business model to deliver patient-centric healthcare.
1998
5.8K+
LTM Revenue $271M
LTM EBITDA $49.3M
$1.3B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
As of September 2025, HCG Hospitals reported last 12-month revenue of $271M and EBITDA of $49.3M.
In the same period, HCG Hospitals generated $200M in LTM gross profit and $6.9M in net income.
See HCG Hospitals valuation multiples based on analyst estimatesIn the most recent fiscal year, HCG Hospitals reported revenue of $248M and EBITDA of $46.8M.
HCG Hospitals expects next 12-month revenue of XXX   and NTM EBITDA of XXX
See HCG Hospitals valuation multiples based on analyst estimatesLTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
---|---|---|---|---|---|---|
Revenue | $271M | XXX | $248M | XXX | XXX | XXX |
Gross Profit | $200M | XXX | $126M | XXX | XXX | XXX |
Gross Margin | 74% | XXX | 51% | XXX | XXX | XXX |
EBITDA | $49.3M | XXX | $46.8M | XXX | XXX | XXX |
EBITDA Margin | 18% | XXX | 19% | XXX | XXX | XXX |
EBIT | $24.8M | XXX | $21.1M | XXX | XXX | XXX |
EBIT Margin | 9% | XXX | 8% | XXX | XXX | XXX |
Net Profit | $6.9M | XXX | $5.0M | XXX | XXX | XXX |
Net Margin | 3% | XXX | 2% | XXX | XXX | XXX |
Net Debt | XXX | XXX | $86.4M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
HCG Hospitals has current market cap of INR 103B (or $1.2B), and EV of INR 119B (or $1.3B).
As of October 17, 2025, HCG Hospitals's stock price is INR 734 (or $8).
See HCG Hospitals trading valuation dataEV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
---|---|---|---|---|---|---|
$1.3B | $1.2B | XXX | XXX | XXX | XXX | $0.05 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialHCG Hospitals's trades at 5.6x EV/Revenue multiple, and 30.1x EV/EBITDA.
See valuation multiples for HCG Hospitals and 15K+ public compsAs of October 17, 2025, HCG Hospitals has market cap of $1.2B and EV of $1.3B.
Equity research analysts estimate HCG Hospitals's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
HCG Hospitals has a P/E ratio of 169.5x.
LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
---|---|---|---|---|---|---|
Market cap (current) | $1.2B | XXX | $1.2B | XXX | XXX | XXX |
EV (current) | $1.3B | XXX | $1.3B | XXX | XXX | XXX |
EV/Revenue | 5.0x | XXX | 5.6x | XXX | XXX | XXX |
EV/EBITDA | 27.3x | XXX | 30.1x | XXX | XXX | XXX |
EV/EBIT | 54.3x | XXX | 66.6x | XXX | XXX | XXX |
EV/Gross Profit | 6.7x | XXX | n/a | XXX | XXX | XXX |
P/E | 169.5x | XXX | 228.1x | XXX | XXX | XXX |
EV/FCF | 101.5x | XXX | 112.8x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialHCG Hospitals's last 12 month revenue growth is 15%
HCG Hospitals's revenue per employee in the last FY averaged $43K, while opex per employee averaged $18K for the same period.
HCG Hospitals's rule of 40 is 33% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
HCG Hospitals's rule of X is 55% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for HCG Hospitals and other 15K+ public compsLTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
---|---|---|---|---|---|---|
Revenue Growth | 15% | XXX | 15% | XXX | XXX | XXX |
EBITDA Margin | 18% | XXX | 19% | XXX | XXX | XXX |
EBITDA Growth | 22% | XXX | 18% | XXX | XXX | XXX |
Rule of 40 | 33% | XXX | 33% | XXX | XXX | XXX |
Bessemer Rule of X | XXX | XXX | 55% | XXX | XXX | XXX |
Revenue per Employee | XXX | XXX | $43K | XXX | XXX | XXX |
Opex per Employee | XXX | XXX | $18K | XXX | XXX | XXX |
S&M Expenses to Revenue | XXX | XXX | 2% | XXX | XXX | XXX |
G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
Opex to Revenue | XXX | XXX | 42% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
EV/Revenue | EV/EBITDA | |||||
---|---|---|---|---|---|---|
2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
Burjeel Holdings | XXX | XXX | XXX | XXX | XXX | XXX |
PureHealth | XXX | XXX | XXX | XXX | XXX | XXX |
Integral Diagnostics | XXX | XXX | XXX | XXX | XXX | XXX |
Monash IVF Group | XXX | XXX | XXX | XXX | XXX | XXX |
Pacific Smiles Group | XXX | XXX | XXX | XXX | XXX | XXX |
XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
HCG Hospitals acquired XXX companies to date.
Last acquisition by HCG Hospitals was XXXXXXXX, XXXXX XXXXX XXXXXX . HCG Hospitals acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiplesAcquired Company | EV | EV/Revenue | EV/EBITDA |
---|---|---|---|
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 65K+ M&A deals.
Start Free TrialWhen was HCG Hospitals founded? | HCG Hospitals was founded in 1998. |
Where is HCG Hospitals headquartered? | HCG Hospitals is headquartered in India. |
How many employees does HCG Hospitals have? | As of today, HCG Hospitals has 5.8K+ employees. |
Who is the CEO of HCG Hospitals? | HCG Hospitals's CEO is Mr. Manish Mattoo. |
Is HCG Hospitals publicy listed? | Yes, HCG Hospitals is a public company listed on NSE. |
What is the stock symbol of HCG Hospitals? | HCG Hospitals trades under HCG ticker. |
When did HCG Hospitals go public? | HCG Hospitals went public in 2016. |
Who are competitors of HCG Hospitals? | Similar companies to HCG Hospitals include e.g. Burjeel Holdings, PureHealth, Integral Diagnostics, Monash IVF Group. |
What is the current market cap of HCG Hospitals? | HCG Hospitals's current market cap is $1.2B |
What is the current revenue of HCG Hospitals? | HCG Hospitals's last 12 months revenue is $271M. |
What is the current revenue growth of HCG Hospitals? | HCG Hospitals revenue growth (NTM/LTM) is 15%. |
What is the current EV/Revenue multiple of HCG Hospitals? | Current revenue multiple of HCG Hospitals is 5.0x. |
Is HCG Hospitals profitable? | Yes, HCG Hospitals is EBITDA-positive (as of the last 12 months). |
What is the current EBITDA of HCG Hospitals? | HCG Hospitals's last 12 months EBITDA is $49.3M. |
What is HCG Hospitals's EBITDA margin? | HCG Hospitals's last 12 months EBITDA margin is 18%. |
What is the current EV/EBITDA multiple of HCG Hospitals? | Current EBITDA multiple of HCG Hospitals is 27.3x. |
What is the current FCF of HCG Hospitals? | HCG Hospitals's last 12 months FCF is $13.3M. |
What is HCG Hospitals's FCF margin? | HCG Hospitals's last 12 months FCF margin is 5%. |
What is the current EV/FCF multiple of HCG Hospitals? | Current FCF multiple of HCG Hospitals is 101.5x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.